Taiwan Bio Industry Organization Election of the 18th Board of
2024-10-25
Taiwan Bio Industry Organization
Election of the 18th Board of Directors, Chairman, and Supervisors
EirGenix Chairman Liu Lee-Cheng elected new Chairman
22 October, 2024
The Taiwan Bio Industry Organization (Taiwan BIO) held its general meeting on October 21 to elect its 18th Board of Directors, Chairman and Supervisors. As a result of the election, Liu Lee-Cheng, Chairman of one of Taiwan’s leading CDMO firms EirGenix, was elected as the new Chairman. The Vice Chairman positions were taken by Chris Tsai, Chairman of Bionet Corp., and Jo Shen, Venture Partner at Vivo Capital.
Nine new members have joined the board of directors and supervisors, including David Chang, CEO, Taiwan Biopharmaceuticals Manufacturing Company (TBMC); Calvin Tsai, CEO, Orient EuroPharma; Lin Shih-Chia, General Manager, TaiAn Technologies; Wu Han-Chung, Director, Biomedical Translational Research Center, Academia Sinica; Eric Chuang, Industrial Technology Research Institute (ITRI), Deputy Director and Director, Biomedical and Medical Technology Institute; Chen Hsiu-Hui, Acting CEO, Development Center for Biotechnology (DCB); Hsieh Hsing-Pang, National Health Research Institutes (NHRI), Director of Biotechnology and Drug Research Institute; Colin Kao, COO of OBI Pharma; and Simon Tsai, National Health Research Institutes (NHRI), Director, Technology Transfer & Incubation Center.
Since its establishment in 1989, Taiwan BIO currently includes 164 organizations, representing 4,000 individuals from industry, government, academic, and research, making it not only the longest-standing bioindustry association in Taiwan but also the most comprehensive. This term’s board members include key figures from the biomedical industry, academic research institutions, and the venture capital community.
Newly elected Chairman Liu Lee-Cheng emphasized underscored the importance of advancing Taiwan's biomedical industry on a global scale. Through collaborations with the global Biotechnology Innovation Organization (BIO) in recent years, the Taiwan BIO has successfully hosted BIO Asia–Taiwan, now the largest biotech event in Asia. Additionally, this year, the association’s Secretary General Wallace Lin was elected Vice Chair of the International Council of Biotechnology Associations (ICBA), further aiding Taiwan’s entry into the global biomedical market and strengthening international connections. Liu hopes to work together with the board and all Taiwan BIO members to actively participate in shaping industry policies, overcoming obstacles and bottlenecks, and helping the biotech industry reach new heights.
The 18th Vice Chairman positions are shared by Chris Tsai, Chairman of Bionet Corp; and Jo Shen, Partner at Vivo Capital. The Executive Supervisor is Jasmine Yu, Health Industry Leader at PwC Taiwan. Two Executive Directors were also elected: Chang Tse-Wen, Chairman of Immunwork; and Audrey Tseng, Honorary Deputy Director at PwC Taiwan and Adjunct Professor at National Yang Ming Chiao Tung University. Previous Chairperson Johnsee Lee was appointed Honorary Chairman, and Chen Chao-Yi was appointed Honorary Supervisor.
Other industry leaders on the new board include: Wendy Huang, Chairman and CEO of AnnJi Pharmaceutical; Wu Chung-Hsiun, Consultant at Bio Aquila; Bobby Sheng, Chairman of Bora Pharmaceuticals; Grace Yeh, Chairman of Onward Therapeutics; James Ho, Chair of Regional Healthcare Practice, CDIB Capital; David Chang, CEO of Taiwan Biopharmaceuticals Manufacturing Company; Lin Shih-Chia, Chairman of TaiAn Technologies; Chen Pei-Jiun, Chairman of Mycenax Biotech; Wu Yon-Lian, Chairman of Sunny Pharmtech; and Daniel Cheng, General Manager of San Fu Biotech.
Government and academic board members include: Wu Han-Chung, Director of the Biomedical Translational Research Center, Academia Sinica; Ting Shih-Tung, Executive Vice President, National Taiwan University; Hsieh Hsing-Pang, Director of the Institute of Biotechnology and Pharmaceutical Research, NHRI; Hung Mien-Chie, President, China Medical University; Chang Wen-Chang, Chair, Taipei Medical University; Kang Jaw-Jou, Distinguished Professor National Yang Ming Chiao Tung University; Wu Jen-Leih, Adjunct Professor, Academia Sinica; Eric Chuang, Industrial Technology Research Institute (ITRI), Deputy Director, and Director, Biomedical and Medical Technology Institute; Chen Hsiu-Hui, Acting CEO, Development Center for Biotechnology (DCB); and Liao Chii-Cherng, Director, Food Industry Research and Development Institute.
In addition to Executive Supervisor Jasmine Yu, other supervisors include Angel Lee, Maywufa Group, Vice Chairman and CEO, PhytoHealth; Colin Kao, COO, OBI Pharma; Liang Chi-Ming, Adjunct Professor, Academia Sinica; and Simon Tsai, Director of the Technology Transfer & Incubation Center, NHRI.
New Chairman Liu Lee-Cheng currently serves as Chairman and CEO of EirGenix and has more than 30 years of experience in product development, process development, and manufacturing in the biotech, pharmaceutical, and specialty chemicals industries. Liu has been an expert planner for the Bio Industry Academy (BIA) and a member of the association's Biosimilars Committee, actively engaging with the government to promote the development of Taiwan’s CDMO and biosimilars industries.
Vice Chairman Chris Tsai is Chairman of Bionet Corp., as well as CEO of GGA Corp and Chairman of Bionet Biologics. With over 25 years of experience in precision medicine R&D and corporate governance, he is currently also Chairman of the Precision Medicine Industry Association of Taiwan and the Taiwan Alliance for Extracellular Vesicles, driving the development of precision medicine and regenerative medicine in Taiwan.
Vice Chairman Jo Shen, founder of ScinoPharm Taiwan, has extensive experience in corporate management and is dedicated to the growth of Taiwan’s bioindustry and the development of its talent. Together with Wu Yon-Lian, Chairman of Sunny Pharmtech, she co-founded the Bio Industry Academy (BIA), dedicated to training industry talent. In recent years, she has also promoted the Taiwan Innovative Drug Alliance, linking the upstream and downstream supply chains of new drug development, connecting over 1,000 biotech professionals domestically and internationally.
Executive Director Chang Tse-Wen, Chairman of Immunwork, is known in Taiwan as the Father of Antibodies. He invented the world's first anti-IgE antibody drug, Xolair, which has since surpassed US$3 billion in global sales. After returning to Taiwan, he served as Dean of the College of Life Science at National Tsing Hua University, Executive Director of the Development Center for Biotechnology (DCB), and Distinguished Researcher at Academia Sinica, long focusing on antibody drug R&D.
Executive Director Audrey Tseng is Honorary Deputy Director at PwC Taiwan and an adjunct professor at National Yang Ming Chiao Tung University. With 35 years of practice experience, Tseng has assisted numerous Taiwanese biotech companies go public and is well-versed in cross-border finance, tax, mergers and acquisitions, and corporate governance.
This July, Taiwan BIO successfully hosted BIO Asia–Taiwan 2024, and will continue holding industry-government networking events, inviting heads of relevant government agencies to engage in dialogue with their industry counterparts to build better communication channels. Courses from the well-regarded Bio Industry Academy (BIA) and other biotech-related seminars are also scheduled and currently open for registration.
Appendix: 18th Board of Directors and Supervisors, Taiwan BIO
Election of the 18th Board of Directors, Chairman, and Supervisors
EirGenix Chairman Liu Lee-Cheng elected new Chairman
22 October, 2024
The Taiwan Bio Industry Organization (Taiwan BIO) held its general meeting on October 21 to elect its 18th Board of Directors, Chairman and Supervisors. As a result of the election, Liu Lee-Cheng, Chairman of one of Taiwan’s leading CDMO firms EirGenix, was elected as the new Chairman. The Vice Chairman positions were taken by Chris Tsai, Chairman of Bionet Corp., and Jo Shen, Venture Partner at Vivo Capital.
Nine new members have joined the board of directors and supervisors, including David Chang, CEO, Taiwan Biopharmaceuticals Manufacturing Company (TBMC); Calvin Tsai, CEO, Orient EuroPharma; Lin Shih-Chia, General Manager, TaiAn Technologies; Wu Han-Chung, Director, Biomedical Translational Research Center, Academia Sinica; Eric Chuang, Industrial Technology Research Institute (ITRI), Deputy Director and Director, Biomedical and Medical Technology Institute; Chen Hsiu-Hui, Acting CEO, Development Center for Biotechnology (DCB); Hsieh Hsing-Pang, National Health Research Institutes (NHRI), Director of Biotechnology and Drug Research Institute; Colin Kao, COO of OBI Pharma; and Simon Tsai, National Health Research Institutes (NHRI), Director, Technology Transfer & Incubation Center.
Since its establishment in 1989, Taiwan BIO currently includes 164 organizations, representing 4,000 individuals from industry, government, academic, and research, making it not only the longest-standing bioindustry association in Taiwan but also the most comprehensive. This term’s board members include key figures from the biomedical industry, academic research institutions, and the venture capital community.
Newly elected Chairman Liu Lee-Cheng emphasized underscored the importance of advancing Taiwan's biomedical industry on a global scale. Through collaborations with the global Biotechnology Innovation Organization (BIO) in recent years, the Taiwan BIO has successfully hosted BIO Asia–Taiwan, now the largest biotech event in Asia. Additionally, this year, the association’s Secretary General Wallace Lin was elected Vice Chair of the International Council of Biotechnology Associations (ICBA), further aiding Taiwan’s entry into the global biomedical market and strengthening international connections. Liu hopes to work together with the board and all Taiwan BIO members to actively participate in shaping industry policies, overcoming obstacles and bottlenecks, and helping the biotech industry reach new heights.
The 18th Vice Chairman positions are shared by Chris Tsai, Chairman of Bionet Corp; and Jo Shen, Partner at Vivo Capital. The Executive Supervisor is Jasmine Yu, Health Industry Leader at PwC Taiwan. Two Executive Directors were also elected: Chang Tse-Wen, Chairman of Immunwork; and Audrey Tseng, Honorary Deputy Director at PwC Taiwan and Adjunct Professor at National Yang Ming Chiao Tung University. Previous Chairperson Johnsee Lee was appointed Honorary Chairman, and Chen Chao-Yi was appointed Honorary Supervisor.
Other industry leaders on the new board include: Wendy Huang, Chairman and CEO of AnnJi Pharmaceutical; Wu Chung-Hsiun, Consultant at Bio Aquila; Bobby Sheng, Chairman of Bora Pharmaceuticals; Grace Yeh, Chairman of Onward Therapeutics; James Ho, Chair of Regional Healthcare Practice, CDIB Capital; David Chang, CEO of Taiwan Biopharmaceuticals Manufacturing Company; Lin Shih-Chia, Chairman of TaiAn Technologies; Chen Pei-Jiun, Chairman of Mycenax Biotech; Wu Yon-Lian, Chairman of Sunny Pharmtech; and Daniel Cheng, General Manager of San Fu Biotech.
Government and academic board members include: Wu Han-Chung, Director of the Biomedical Translational Research Center, Academia Sinica; Ting Shih-Tung, Executive Vice President, National Taiwan University; Hsieh Hsing-Pang, Director of the Institute of Biotechnology and Pharmaceutical Research, NHRI; Hung Mien-Chie, President, China Medical University; Chang Wen-Chang, Chair, Taipei Medical University; Kang Jaw-Jou, Distinguished Professor National Yang Ming Chiao Tung University; Wu Jen-Leih, Adjunct Professor, Academia Sinica; Eric Chuang, Industrial Technology Research Institute (ITRI), Deputy Director, and Director, Biomedical and Medical Technology Institute; Chen Hsiu-Hui, Acting CEO, Development Center for Biotechnology (DCB); and Liao Chii-Cherng, Director, Food Industry Research and Development Institute.
In addition to Executive Supervisor Jasmine Yu, other supervisors include Angel Lee, Maywufa Group, Vice Chairman and CEO, PhytoHealth; Colin Kao, COO, OBI Pharma; Liang Chi-Ming, Adjunct Professor, Academia Sinica; and Simon Tsai, Director of the Technology Transfer & Incubation Center, NHRI.
New Chairman Liu Lee-Cheng currently serves as Chairman and CEO of EirGenix and has more than 30 years of experience in product development, process development, and manufacturing in the biotech, pharmaceutical, and specialty chemicals industries. Liu has been an expert planner for the Bio Industry Academy (BIA) and a member of the association's Biosimilars Committee, actively engaging with the government to promote the development of Taiwan’s CDMO and biosimilars industries.
Vice Chairman Chris Tsai is Chairman of Bionet Corp., as well as CEO of GGA Corp and Chairman of Bionet Biologics. With over 25 years of experience in precision medicine R&D and corporate governance, he is currently also Chairman of the Precision Medicine Industry Association of Taiwan and the Taiwan Alliance for Extracellular Vesicles, driving the development of precision medicine and regenerative medicine in Taiwan.
Vice Chairman Jo Shen, founder of ScinoPharm Taiwan, has extensive experience in corporate management and is dedicated to the growth of Taiwan’s bioindustry and the development of its talent. Together with Wu Yon-Lian, Chairman of Sunny Pharmtech, she co-founded the Bio Industry Academy (BIA), dedicated to training industry talent. In recent years, she has also promoted the Taiwan Innovative Drug Alliance, linking the upstream and downstream supply chains of new drug development, connecting over 1,000 biotech professionals domestically and internationally.
Executive Director Chang Tse-Wen, Chairman of Immunwork, is known in Taiwan as the Father of Antibodies. He invented the world's first anti-IgE antibody drug, Xolair, which has since surpassed US$3 billion in global sales. After returning to Taiwan, he served as Dean of the College of Life Science at National Tsing Hua University, Executive Director of the Development Center for Biotechnology (DCB), and Distinguished Researcher at Academia Sinica, long focusing on antibody drug R&D.
Executive Director Audrey Tseng is Honorary Deputy Director at PwC Taiwan and an adjunct professor at National Yang Ming Chiao Tung University. With 35 years of practice experience, Tseng has assisted numerous Taiwanese biotech companies go public and is well-versed in cross-border finance, tax, mergers and acquisitions, and corporate governance.
This July, Taiwan BIO successfully hosted BIO Asia–Taiwan 2024, and will continue holding industry-government networking events, inviting heads of relevant government agencies to engage in dialogue with their industry counterparts to build better communication channels. Courses from the well-regarded Bio Industry Academy (BIA) and other biotech-related seminars are also scheduled and currently open for registration.
Appendix: 18th Board of Directors and Supervisors, Taiwan BIO
| Title | Name | Organization/Position |
| Chairman | Liu Lee-Cheng | EirGenix, Chairman and CEO |
| Vice Chairman | Chris Tsai | Bionet Corp, Chairman |
| Vice Chairman | Jo Shen | Vivo Capital, Partner |
| Executive Director | Chang Tse-Wen | Immunwork, Chairman and CEO |
| Executive Director | Audrey Tseng | National Yang Ming Chiao Tung University, Adjunct Professor |
| Director | James Ho | CDIB Capital Group, Chair of Regional Healthcare Practice |
| Honorary Chair | Johnsee Lee | Personal Genomics Taiwan, Chairman |
| Director | Wu Yon-Lian | Sunny Pharmtech, Chairman and CEO |
| Director | Wu Chung-Hsiun | Bio Aquila, Consultant |
| Director | Howard Lee | Taho Biopharmaceuticals, Chairman |
| Director | Lin Shih-Chia | TaiAn Technologies, General Manager |
| Director | David Chang | Taiwan Biopharmaceutical Manufacturing Company (TBMC), CEO |
| Director | Bobby Sheng | Bora Pharmaceuticals, Chairman |
| Director | Chen Pei-Jiun | Mycenax Biotech, Chairman and CEO |
| Director | Wendy Huang | AnnJi Pharmaceutical, Chairman and CEO |
| Director | Grace Yeh | Onward Therapeutics, Chairman and CEO |
| Director | Calvin Tsai | Orient EuroPharma, CEO |
| Director | Daniel Cheng | San Fu Biotech, General Manager |
| Director | Ting Shih-Tung | National Taiwan University, Executive Vice President |
| Director | Wu Jen-Leih | Academia Sinica, Adjunct Professor |
| Director | Wu Han-Chung | Academia Sinica, Director of the Biomedical Translational Research Center |
| Director | Hung Mien-Chie | China Medical University, President |
| Director | Kang Jaw-Jou | National Yang Ming Chiao Tung University, Distinguished Professor |
| Director | Chang Wen-Chang | Taipei Medical University, Chair (Academia Sinica Academician) |
| Director | Eric Chuang | Industrial Technology Research Institute (ITRI), Deputy Director and Director of Biomedical and Medical Technology Institute |
| Director | Chen Hsiu-Hui | Development Center for Biotechnology (DCB), Acting CEO |
| Director | Liao Chii-Cherng | Food Industry Research and Development Institute, Director |
| Director | Hsieh Hsing-Pang | National Health Research Institutes (NHRI), Director, Institute of Biotechnology and Pharmaceutical Research |
| Supervisory Director | Name | Organization/Position |
| Executive Supervisor | Jasmine Yu | PwC Taiwan, Health Industry Leader |
| Honorary Supervisor | Chen Chao-Yi | Taiwan Sugar Corporation, Former Chairman |
| Supervisor | Angel Lee | Maywufa PhytoHealth Group, Vice Chairman and CEO of PhytoHealth |
| Supervisor | Colin Kao | OBI Pharma, Chief Operating Officer |
| Supervisor | Liang Chi-Ming | Academia Sinica, Adjunct Professor |
| Supervisor | Simon Tsai | National Health Research Institutes (NHRI), Director, Technology Transfer & Incubation Center |